In April 2026, VinFast Auto highlighted the VF 8 Eco’s Pininfarina-designed styling, 256-mile range, competitive financing, and US$39,900 starting price, while also reporting March Vietnam EV deliveries of 27,609 units and 53,684 units for the first quarter, showing very large year-over-year growth and reinforcing its position in the domestic market. This combination of strong product appeal and rapidly rising domestic deliveries suggests VinFast is gaining meaningful traction with...

The European markets have shown mixed performance recently, with the pan-European STOXX Europe 600 Index edging up slightly due to dovish signals from the U.S. Federal Reserve and easing trade tensions between the U.S. and China. In this context, investors are exploring diverse opportunities, including those in smaller or newer companies that offer affordability and growth potential. While 'penny stocks' might seem like a term from a bygone era, they continue to represent viable investment...

If you are weighing your next move with Banca IFIS, you are not alone. After all, the stock has served up a mix of intrigue and promise this year, catching plenty of attention across the financial landscape. In the past week, the share price edged down just 0.8%, but zoom out a bit and the bigger story comes into focus. The stock is up 4.1% over the past month, 9.2% year to date, and a striking 20.5% over the past twelve months. Stretch that time frame further, and Banca IFIS has rewarded...

The cider brand has added a high-contrast NaviLens QR code to its cans.

BioReference health, JPMorgan Chase and an Italian fashion retailer are making the job cuts amid market uncertainty

Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said.